Cadrenal Therapeutics registers 590,001 shares

Cadrenal Therapeutics registered 590,001 shares of Common Stock for resale under a prospectus supplement to its Form S-3 registration statement.

Rhea-AI Filing Summary

Cadrenal Therapeutics registered 590,001 shares of Common Stock for resale under a prospectus supplement to its Form S-3 registration statement. The supplement states that 571,430 of those shares are issuable upon exercise of Existing Warrants that were amended on March 31, 2026 to reduce the exercise price from $16.50 to $4.50. The supplement covers resale "from time to time," and the prospectus remains qualified by the underlying Form S-3 prospectus.

The company reports a Nasdaq closing price of $5.12 per share as of March 31, 2026. The supplement updates warrant terms and registers the related shares; other prospectus terms continue to apply.

Key Figures

Registered shares: 590,001 shares Warrants issuable: 571,430 shares Old exercise price: $16.50 +2 more

5 metrics

Registered shares 590,001 shares resale registration under Form S-3 prospectus supplement

Warrants issuable 571,430 shares shares issuable upon exercise of Existing Warrants referenced in the supplement

Old exercise price $16.50 previous exercise price per Existing Warrant

New exercise price $4.50 amended exercise price per Existing Warrant as of March 31, 2026

Nasdaq closing price $5.12 closing price per share on Nasdaq as of March 31, 2026

Key Terms

Prospectus supplement, Existing Warrants, Private Placement

3 terms

Prospectus supplement regulatory

"This prospectus supplement updates, amends and supplements the prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Existing Warrants financial

"571,430 shares of Common Stock issuable upon the exercise of common warrants"

Private Placement financial

"purchased by an investor in a private placement transaction that closed on or about November 4, 2024"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Offering Details

resale

Offering

Offering Type resale

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the prospectus supplement for CVKD register?

It registers 590,001 shares of Common Stock for resale. The supplement updates the Form S-3 registration to permit resale of up to 590,001 shares, including 571,430 shares issuable upon exercise of amended Existing Warrants.

How many warrants were amended and what changed for CVKD?

571,430 warrants were amended. On March 31, 2026 the exercise price for those Existing Warrants was reduced from $16.50 to $4.50 per share, as disclosed in the prospectus supplement dated April 1, 2026.

Will Cadrenal receive proceeds from sales under this registration?

The prospectus describes resale of registered shares. The supplement updates resale registration; the document does not specify proceeds treatment beyond resale registration language in the underlying prospectus.

What is the market price context included in the supplement?

Cadrenal reported a Nasdaq closing price of $5.12 per share. That price is cited as of March 31, 2026 and is provided in the supplement for reference alongside the warrant amendment disclosure.

When did the warrant amendment take effect for CVKD?

The amendment was entered on March 31, 2026. The prospectus supplement is dated April 1, 2026 and states the amendment to the exercise price occurred on March 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 07:30 AM Learn about SEC filing dates

Filed pursuant to Rule 424(b)(5)

Registration No. 333-283226

PROSPECTUS SUPPLEMENT NO. 1

(to the prospectus dated November 22, 2024)

Cadrenal Therapeutics, Inc.

590,001 Shares of Common Stock

This prospectus supplement updates, amends and supplements the prospectus contained in the Registration Statement on Form S-3, declared effective as of November 22, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-283226) relating to the resale from time to time of up to 590,001 shares of common stock, par value $0.001 per share (the “Common Stock”), of Cadrenal Therapeutics, Inc. (the “Company”), including, in part, 571,430 shares of Common Stock issuable upon the exercise of common warrants to purchase shares of Common Stock (the “Existing Warrants”) purchased by an investor in a private placement transaction that closed on or about November 4, 2024 (the “Private Placement”). This prospectus supplement is being filed in connection with an amendment to certain of the Existing Warrants as described below under “Amendments to Existing Warrants.” Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Our shares of Common Stock are listed on the Nasdaq Capital Market under the symbol “CVKD”. On March 31, 2026, the closing price for our shares of Common Stock on the Nasdaq Capital Market was $5.12 per share.

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties under the heading “Risk Factors” beginning on page 5 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

AMENDMENTS TO EXISTING WARRANTS

This prospectus supplement is being filed to disclose the following:

On March 31, 2026, we entered into an amendment with a holder of Existing Warrants to purchase up to 571,430 shares of Common Stock held in the aggregate by such holder in order to amend the exercise price under such Existing Warrants from $16.50 to $4.50 per share.

The date of this prospectus supplement is April 1, 2026.